Version françaiseEnglish version
RD Biotech / Molecular biology / Biologie MoléculaireRD Biotech / Services analytiques / Analytical servicesRD Biotech / Anticorps monoclonaux (mAb) / Monoclonal antibodiesRD Biotech / ELISARD Biotech / Culture Cellulaire / Cell cultureRD Biotech / Production de cellules / Cell production



3 rue Henri Baigue

F-25000 Besançon

+33(0)3 81 53 88 37

Biotech Investissement

RD-BIOTECH is now a sister company of DIACLONE and SYNABS, for a better synergy in the field of monoclonal antibodies!

Read more

Careers with RD Biotech

Please apply using the online application form



... … Maximise your research potential in partnership with RD-Biotech.

RD Biotech

RD-Biotech is a biotechnology company that offers customised solutions in Genomics, Immunology and Cell Engineering, as part of Research and Development programs or Pre-clinical studies.

- The benefits of an R & D contract enables development of quality controlled biological reagents and tools such as hybridomas, cell lines, vectors etc in parallel with enhancement of protocols and methods.

- A production service contract is available for: monoclonal antibodies, recombinant proteins, cell lines, plasmids, nucleic acid preparation ‚…

- Analytical services: ELISA, Western Blotting, cytometry, Octet, PCR and qPCR, bioassays platform to study biological activities of antibodies (ADCC, CDC, assay of proliferation…)

- Our FastELISA product range also includes ready-to-use ELISA kits and reagent for the quantification of human, mouse, rat immunoglobulins, protein A quantification...

Since its inception in 2002, RD-Biotech has provided expertise and scientific know-how to offer customers a personalized, confidential, interactive and quality service.

We exceed our customers' expectations through high-level technical solutions, while optimizing budgets.

The expertise of our multidisciplinary team and the quality of our services make and have made RD-BIOTECH a trusted partner of major national and international companies and academic institutes alike.

Our main business sectors:
- Pharmaceutic
- In vitroDiagnosis
- Animal Health
- Dermo-cosmetic
- Public laboratory


...A team of experiemented researchers

Your contacts:

Philippe Dulieu, PhD:

Sylvie Mercier, PhD:
Sale and Communication manager France

Jean-Luc Schlick, PhD:
Products & services manager

Jean-François Musard, PhD:
Laboratory manager

"We have the ambition to become a partner of choice in the realization of your projects by making you save time and by allowing you to reduce your costs of functioning"
Philippe Dulieu, president of RD-BIOTECH


...…RD-Biotech is at your disposal to meet your needs and optimize your research programs.

RD Biotech

With an extensive versatile technical platform, coupled to over 500 m2 of independent laboratory space equipped and maintained to the highest standard

- We have automated systems for the preparation of RNA and our cell culture system for example has a capacity of over 300 liters.

- As a partner of the University of Franche Comté and the regional blood transfusion center, our team has access to DNA sequencing, cell sorting and con-focal microscopy platforms

Therefore, RD-BIOTECH is able to aid your research projects at all stages.



The mAbexterts group

The mAbexterts group

Visit the website to discover more:


Biotech Investissement (France), majority shareholder of RD-BIOTECH, acquired the company Diaclone SAS from the Group Hologics Gen-Probe (USA) on October 2, 2012.
With 25 years of experience and expertise, Diaclone is recognized worldwide for the excellence of its wide range of products in Immunology, including monoclonal antibodies, ELISA kits, ELISpot and multiplex assays.
The covered research areas are: apoptosis, cytokines, cytokine receptors, chemokines, CD markers and adhesion molecules.

RD-Biotech is convinced that the synergy between the companies will create strong added value to their customers and that this merger will give them more opportunities to work more closely with all their partners.

• Monoclonal antibodies
• ELISpot
• Multiplex

Visit the website to discover more...:


Majority stake in SynAbs, created in September 2015 in Leuven (Belgium).

A 30-year expertise in monoclonal antibodies range of more than 100 secondary monoclonal antibodies: anti-mouse, human, rat, many other species as well as isotype controls Innovative expertise in the development of monoclonal antibodies in rats and guinea pigs.


Visit the website to discover more :


2018: Entry into the capital of QVQ holding, company based in Utrecht (The Netherlands).

QVQ has strong expertise in the development and production of single domain antibodies derived from llamas, which are referred to as VHHs.
By joining the mAbexperts team, QVQ will complement the high level of expertise already present within the group, to develop and market new high-quality diagnostic assays and imaging products.


Visit the website to discover more :


2020: Entry into the capital of SMALTIS SAS, a company based in Besançon (France).

Created in 2014, SMALTIS has a solid expertise in Microbiology and an innovative experience in Bacterial Genetics.
By joining the mAbexperts group, SMALTIS is consolidating already well-established expertise in the fields of Bioproduction and related quality controls, by adding Microbiological and Bacterial Genetic Engineering expertise.


Visit the website to discover more :


- Poster : “High Quality Grade” Plasmid production platform as a scale-up tool for new innovative therapeutics
- Poster : Wheat germ cell-free expression system: An alternative method for the production of functional membrane and toxic proteins